Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Study Information
Alliance Study ID: A222001
NCT Study ID (ClinicalTrials.gov): NCT04600336
Alliance Committee: Cancer Control
Disease or Cancer Type: Prostate Cancer
Alliance Study Chair: Bradley J. Stish, MD
Status: COMPLETED
Study Description
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information